Theriva Biologics Secures $7.5M Investment to Accelerate Next-Generation Oncology & GI Therapeutics Development

Theriva Biologics, Inc. (NYSE American: TOVX) is thrilled to announce a significant milestone in its journey to revolutionize the treatment of life-threatening diseases. The company has successfully raised $7.5 million in its latest funding round, a crucial investment that will accelerate the development of its innovative therapeutic candidates. With a keen focus on addressing areas of high unmet medical need, Theriva Biologics continues to push the boundaries of science and medicine. Following the strategic acquisition of VCN Biosciences, S.L., the company expanded its oncology platform by integrating a novel oncolytic adenovirus technology. This breakthrough platform is not only designed for targeted delivery through intravenous and intravitreal routes but also works to overcome the formidable tumor stroma barrier, enhancing drug access and sparking potent anti-tumor immune responses. The raised capital will be predominantly directed toward advancing the development of Theriva’s lead candidates, including VCN-01, a precision-engineered oncolytic adenovirus that selectively replicates within tumor cells to induce cell death, and SYN-004 (ribaxamase), aimed at protecting the gut microbiome by degrading certain IV beta-lactam antibiotics. Funds will also support further progress of SYN-020, a recombinant oral formulation of intestinal alkaline phosphatase, which holds promise for treating a broad spectrum of local gastrointestinal and systemic diseases. This infusion of capital not only affirms investor confidence in the company’s innovative approach but also underscores its commitment to delivering next-generation therapeutics that can transform patient outcomes and redefine cancer and GI disease treatment paradigms.